Orexo to present clinical data for OX640 at the EAACI Congress

Orexo Sweden

OX640 is a nasal rescue medication with powder-based epinephrine for the treatment of severe allergic reactions (including anaphylaxis) and is based on the proprietary AmorphOX® technologyEAACI is a leading global association devoted to allergic and immunology diseasesOrexo´s advisor Dr. Anne K Ellis, Professor and Chair of the Division of Allergy & Immunology at Queen's University, Ontario, CA, will present data from the OX640-002 clinical study. View original content:https://www.prnewswire.co.uk/news-releases/orexo-to-present-clinical-data-for-ox640-at-the-eaaci-congress-302470710.html